ESC ACS 2023 Flashcards
Fibrinolysis combined with rescue PCI (in cases of failed fibrinolysis) or routine early PCI strategy (in cases of successful fibrinolysis)
Pharmaco-invasive strategy
ACS Spectrum
Classification of patients suspected of ACS
In patients with a working diagnosis of STEMI, a _______ strategy (i.e. immediate angiography and PCI as needed) is the preferred reperfusion strategy
PPCI
For patients who undergo fibrinolysis, _____________ is indicated if fibrinolysis fails (i.e. ST-segment resolution <50% within 60–90 min of fibrinolytic administration) or in the presence of haemodynamic or electrical instability, worsening ischaemia, or persistent chest pain.
Rescue PCI
Patients with successful fibrinolysis should undergo early invasive angiography (i.e. within ________ from the time of the lytic bolus injection)
2–24 h
Modes of presentation and pathways to invasive management and myocardial revascularization in patients presenting with STEMI
Goals:
Ischemic time
Door to wiring
Door to needle
<120mins
<90mins
<10mins
Criteria for VHR NSTEMI
Haemodynamic instability or cardiogenic shock
Recurrent or ongoing chest pain refractory to medical treatment
Acute heart failure presumed secondary to ongoing myocardial ischaemia
Life-threatening arrhythmias or cardiac arrest after presentation
Mechanical complications
Recurrent dynamic ECG changes suggestive of ischaemia
Rescue PCI for failed fibrinolysis is Class ______ recommendation
Class I
Give dosing of Tirofiban
Bolus of 25 mcg/kg i.v. over 3 min, followed by an infusion of 0.15 mcg/kg/min for up to 18 h.
In p tients with a working diagnosis of NSTE-ACS, routine pre-treatment with a __________________ before knowing the coronary anatomy in patients anticipated to undergo an early invasive strategy (i.e. <24 h) is not recommended.
P2Y 12 receptor inhibitor
Alternative antiplatelet strategies to reduce bleeding risk in the first 12 months after an ACS.
____________. is recommended irrespective of the treatment strategy (invasive or conservative)
Ticagrelor (180 mg LD, 90 mg b.i.d. MD)
As the default strategy for patients with atrial fibrillation and CHA2 DS2 -VASc score ≥1 in men and ≥2 in women, after up to __________ of triple antithrombotic therapy following the ACS event, dual antithrombotic therapy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel) for up to 12 months is recommended.
1 week
In patients who are event-free after __________ of DAPT and who are not high ischaemic risk, single antiplatelet therapy (preferably with a P2Y12 receptor inhibitor)
3–6 months